focus -WSS

focus

author：explore 2025-10-02 06:19:00 - browse：9643

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Long Covid needs a new name — and a new frame

knowledge

WSS

FDA approves updated Covid vaccines

FDA panel endorses Alnylam’s heart drug — after picking it apart

How to make the FDA’s new prescription one

A common UTI test for kids haunts adults as a traumatic 'nightmare'

New weight loss drugs vying to be the next Wegovy or Mounjaro

Telehealth for opioid use disorder is lifesaving

leisure time

focus

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Telehealth for opioid use disorder is lifesaving

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA panel endorses Alnylam’s heart drug — after picking it apart

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Healthy food access boosts outcomes in two studies

23andMe had bad news about my health. I wish a person had delivered it

Weight loss drugs should be covered by insurers, AMA says

Activists slam private health insurers over coverage restrictions

Today's health inequities arise from racist U.S. history, say experts

focus

Diverse clinical trials: Why aren’t we there yet?

Popular nasal decongestant doesn't actually relieve congestion

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

PEPFAR is under serious threat — and so is global health

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Diverse clinical trials: Why aren’t we there yet?

entertainment

knowledge

explore

Wikipedia